Evidence map›Paper›PMID 39138765›Full record

ArticleAAPS PharmSciTech2024

Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability.

Shuyin Liu, Hui Chen, Feng Zhou, Sandip Tiwari, Kai Zhuang, Yudong Shan, Jiantao Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuyin LiuCixi Biomedical Research Institute, Wenzhou Medical University, Cixi, 315300, China.
Hui ChenLaboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo, 315201, China.
Feng ZhouLaboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo, 315201, China.
Sandip TiwariPharma Solutions, BASF Corp., 500 White Plains Rd, Tarrytown, NY, 10591, USA.
Kai ZhuangPharma Solutions, Nutrition and Health, BASF (China) Company, Ltd, 333 Jiang Xin Sha Road, Shanghai, 200137, China.
Yudong ShanHangzhou Zhongmeihuadong Pharmaceutical Co., Ltd., 866 Moganshan Road, Hangzhou, 310011, China.
Jiantao ZhangCixi Biomedical Research Institute, Wenzhou Medical University, Cixi, 315300, China. Zhangjiantao@nimte.ac.cn.ORCID http://orcid.org/0009-0005-7987-8856

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dissolution and bioavailability challenges posed by poorly water-soluble drugs continue to drive innovation in pharmaceutical formulation design. Nintedanib (NDNB) is a typical BCS class II drug that has been utilized to treat idiopathic pulmonary fibrosis (IPF). Due to the low solubility, its oral bioavailability is relatively low, limiting its therapeutical effectiveness. It is crucial to enhance the dissolution and the oral bioavailability of NDNB. In this study, we focused on the preparation of amorphous solid dispersions (ASD) using hot melt extrusion (HME). The formulation employed Kollidon

Indexed as

Biological AvailabilityIndolesSolubilityAdministration, OralAnimalsCalorimetry, Differential ScanningChemistry, PharmaceuticalDrug CompoundingDrug LiberationHot Melt Extrusion TechnologyMalePolymersRabbitsSpectroscopy, Fourier Transform InfraredX-Ray DiffractionIndolesnintedanibPolymersamorphous solid dispersionhot melt extrusionnintedaniboral bioavailability

Identifiers

PMID39138765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.